Awards & Recognition
Between 2018 and 2024, Biotts received recognition across pharmaceutical industry programs, startup competitions, and technology innovation awards. This external validation – from organizations including Deloitte, Pfizer, MIT Enterprise Forum, and the Advanced Technologies & Treatments for Diabetes (ATTD) Conference – reflects progress in both transdermal platform development and commercial model viability as the company advanced from research-stage startup to clinical-stage development company.
Timeline
2018
- Finalist – MIT Enterprise Forum Poland
2019
- 1st Place – Economic Forum
- 1st Place – Central European BioForum (CEBioForum)
- 1st Place – BioMed Polish Development Fund Academy
- 2nd Place – MedTrends
2020
- 1st Place – Start-Up Challenge in Health and Biotechnology, XII European Economic Congress
- Finalist – InCredibles Programme
- Finalist – BioForum CE
2021
- “Impact Star” Award – Deloitte Technology Fast 50 Central Europe (recognizing both scientific innovation and commercial potential in drug delivery technology)
- Finalist – Google for Startups
2022
- 1st Place – 5th Forum of Modern Diabetology
2024
- 1st Place – ATTD Conference (Advanced Technologies & Treatments for Diabetes)
Additional Recognition
- Finalist – Pfizer PACTT (Preclinical Trials Academy)
These awards provided early validation and visibility during Biotts’ transition from research-stage startup to clinical-stage development company. Today, the company’s capabilities are defined by operational milestones: a GMP-certified R&D facility, an international patent portfolio with grants in Poland, Canada, and the United States, Phase 1 clinical completion for a transdermal SGLT2 inhibitor, breakthrough insulin delivery achievement (55% bioavailability, 5-day sustained release), and strategic partnerships with Bioton S.A. and Servier.
For a complete company timeline including development milestones, intellectual property progress, and partnership announcements, see Company History.